ArticleAmerican journal of translational research2026
Prognostic nomogram for acute cerebral infarction based on risk factors: treatment with urinary kallidinogenase and edaravone-dexborneol.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the prognostic factors in patients with acute cerebral infarction (ACI) treated with urinary kallidinogenase combined with edaravone-dexborneol and to construct a predictive model.
methodsA total of 120 ACI patients admitted to Dongyang People's Hospital, affiliated to Wenzhou University, from January 2022 to December 2023 were retrospectively collected, of whom 101 were included after screening. An additional 105 ACI patients admitted to other hospitals during the same period were collected as an external validation cohort. Prognosis was assessed using the modified Rankin Scale (mRS), and patients were classified into the good prognosis group (mRS ≤ 2 points) and the poor prognosis group (mRS > 2 points). Clinical data of the two groups were collected for univariate and binary logistic regression analyses to construct a nomogram prediction model, and ROC curve analysis was used to validate the predictive performance.
resultsUnivariate analysis indicated that comorbidities, TOAST classification, infarct location, thrombolytic/anticoagulant therapy drugs, age, disease duration, National Institutes of Health Stroke Scale (NIHSS) score at admission, Glasgow Coma Scale (GCS) score at admission, and fasting blood glucose were factors associated with poor prognosis. Binary logistic regression analysis showed that brainstem infarction, clopidogrel as thrombolytic/anticoagulant therapy, and NIHSS score at admission were independent risk factors. Model Y was constructed, and the Hosmer-Lemeshow test yielded χ
conclusionThe prognosis of ACI patients treated with urinary kallidinogenase combined with edaravone-dexborneol is influenced by multiple factors. Clinicians may construct a prognostic prediction model based on previous medical records to identify risk factors and adjust treatment strategies to improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.